Cytokinetics details trial win for what could be its next approval The company’s drug aficamten hit both its endpoints in a study in a condition known as nHCM

https://www.statnews.com/2026/08/28/cytokinetics-myqorzo-aficamten-nhcm-acacia-trial-success/ By Andrew JosephAug. 28, 2026 Europe Correspondent